[1]
|
Salter, B.S., et al. (2016) Heparin-Induced Thrombocytopenia: A Comprehensive Clinical Review. Journal of the Amer-ican College of Cardiology, 67, 2519-2532. https://doi.org/10.1016/j.jacc.2016.02.073
|
[2]
|
Cuker, A., et al. (2018) American Society of Hematology 2018 Guidelines for Management of Venous Thromboembolism: Heparin-Induced Thrombocytopenia. Blood Advances, 2, 3360-3392.
https://doi.org/10.1182/bloodadvances.2018024489
|
[3]
|
Hirsh, J., et al. (2001) Heparin and Low-Molecular-Weight Heparin: Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety. Chest, 119, 64S-94S. https://doi.org/10.1378/chest.119.1_suppl.64S
|
[4]
|
Tran, A., et al. (2022) Efficacy and Safety of Low Molecular Weight Heparin versus Unfractionated Heparin for Prevention of Venous Thromboembolism in Trauma Patients. Annals of Surgery, 275, 19-28.
https://doi.org/10.1097/SLA.0000000000005157
|
[5]
|
Guyatt, G.H., et al. (2012) Executive Summary: Antithrom-botic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 141, 7S-47S.
https://doi.org/10.1378/chest.141.4.1129a
|
[6]
|
Bauersachs, R.M. (2023) Fondaparinux Sodium: Recent Advances in the Management of Thrombosis. Journal of Cardiovascular Pharmacology and Therapeutics, 28. https://doi.org/10.1177/10742484221145010
|
[7]
|
Dempfle, C., et al. (2021) Fondaparinux Pre-, Peri-, and/or Postpartum for the Prophylaxis/Treatment of Venous Thromboembolism (FondaPPP). Clinical and Applied Throm-bosis/Hemostasis, 27.
https://doi.org/10.1177/10760296211014575
|
[8]
|
李莹, 等. 利伐沙班在深静脉血栓形成患者中的药动学研究[J]. 中国药学杂志, 2018, 53(20): 1768-1774.
|
[9]
|
Essien, E.O., Rali, P. and Mathai, S.C. (2019) Pulmonary Embo-lism. Medical Clinics of North America, 103, 549-564.
https://doi.org/10.1016/j.mcna.2018.12.013
|
[10]
|
Kim, I.S., et al. (2019) Non-Vitamin K Antagonist Oral Anticoag-ulants with Amiodarone, P-Glycoprotein Inhibitors, or Polypharmacy in Patients with Atrial Fibrillation: Systematic Re-view and Meta-Analysis. Journal of Cardiology, 73, 515-521. https://doi.org/10.1016/j.jjcc.2018.12.018
|
[11]
|
Vazquez, S.R. (2018) Drug-Drug Interactions in an Era of Multiple Anticoagulants: A Focus on Clinically Relevant Drug Interactions. Hematology, ASH Education Program, 2018, 339-347.
https://doi.org/10.1182/asheducation-2018.1.339
|
[12]
|
Yan, Z., et al. (2019) The Relationship between Red Blood Cell Distribution Width and Metabolic Syndrome in Elderly Chinese: A Cross-Sectional Study. Lipids in Health and Disease, 18, Article No. 34.
https://doi.org/10.1186/s12944-019-0978-7
|
[13]
|
Eikelboom, J.W., et al. (2013) Dabigatran versus Warfarin in Pa-tients with Mechanical Heart Valves. The New England Journal of Medicine, 369, 1206-1214. https://doi.org/10.1056/NEJMoa1300615
|
[14]
|
Büller, H.R., et al. (2013) Edoxaban versus Warfarin for the Treat-ment of Symptomatic Venous Thromboembolism. The New England Journal of Medicine, 369, 1406-1415. https://doi.org/10.1056/NEJMoa1306638
|
[15]
|
Stacy, Z.A., et al. (2016) Edoxaban: A Comprehensive Review of the Pharmacology and Clinical Data for the Management of Atrial Fibrillation and Venous Thromboembolism. Cardiolo-gy and Therapy, 5, 1-18.
https://doi.org/10.1007/s40119-016-0058-2
|
[16]
|
Kearon, C., et al. (2016) Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest, 149, 315-352. https://doi.org/10.1016/j.chest.2015.11.026
|
[17]
|
Smythe, M.A., et al. (2016) Guidance for the Practical Manage-ment of the Heparin Anticoagulants in the Treatment of Venous Thromboembolism. Journal of Thrombosis and Throm-bolysis, 41, 165-186.
https://doi.org/10.1007/s11239-015-1315-2
|
[18]
|
Mai, V., et al. (2021) Direct Oral Anticoagulants in the Treatment of Acute Venous Thromboembolism in Patients with Obesity: A Systematic Review with Meta-Analysis. Pharmacolog-ical Research, 163, Article ID: 105317.
https://doi.org/10.1016/j.phrs.2020.105317
|
[19]
|
Martin, K.A., et al. (2021) Use of Direct Oral Anticoagulants in Patients with Obesity for Treatment and Prevention of Venous Thromboembolism: Updated Communication from the ISTH SSC Subcommittee on Control of Anticoagulation. Journal of Thrombosis and Haemostasis, 19, 1874-1882. https://doi.org/10.1111/jth.15358
|
[20]
|
Hindricks, G., et al. (2021) 2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation Developed in Collaboration with the European Association for Cardio-Thoracic Sur-gery (EACTS): The Task Force for the Diagnosis and Management of Atrial Fibrillation of the European Society of Car-diology (ESC) Developed with the Special Contribution of the European Heart Rhythm Association (EHRA) of the ESC. European Heart Journal, 42, 373-498.
https://doi.org/10.1093/eurheartj/ehaa612
|
[21]
|
Wu, H. and Nguyen, G.C. (2010) Liver Cirrhosis Is Associated with Venous Thromboembolism among Hospitalized Patients in a Nationwide US Study. Clinical Gastroenterology and Hepatology, 8, 800-805.
https://doi.org/10.1016/j.cgh.2010.05.014
|
[22]
|
Khorana, A.A., et al. (2022) Cancer-Associated Venous Throm-boembolism. Nature Reviews Disease Primers, 8, 11.
https://doi.org/10.1038/s41572-022-00336-y
|
[23]
|
Beyer-Westendorf, J., et al. (2019) Non-Vitamin K Antagonist Oral Anticoagulants (NOAC) as an Alternative Treatment Option in Tumor-Related Venous Thromboembolism. Deutsches Ärzteblatt International, 116, 31-38.
https://doi.org/10.3238/arztebl.2019.0031
|
[24]
|
Konstantinides, S.V., et al. (2019) 2019 ESC Guidelines for the Diagnosis and Management of Acute Pulmonary Embolism Developed in Collaboration with the European Respiratory Society (ERS). European Respiratory Journal, 54, Article ID: 1901647.
|
[25]
|
Agnelli, G., et al. (2020) Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. The New England Journal of Medicine, 382, 1599-1607. https://doi.org/10.1056/NEJMoa1915103
|
[26]
|
Lyman, G.H., et al. (2021) American Society of Hema-tology 2021 Guidelines for Management of Venous Thromboembolism: Prevention and Treatment in Patients with Can-cer. Blood Advances, 5, 927-974.
https://doi.org/10.1182/bloodadvances.2020003442
|
[27]
|
Lim, W., et al. (2018) American Society of Hematology 2018 Guidelines for Management of Venous Thromboembolism: Diagnosis of Venous Thromboembolism. Blood Ad-vances, 2, 3226-3256.
https://doi.org/10.1182/bloodadvances.2018024828
|
[28]
|
Regitz-Zagrosek, V., et al. (2018) 2018 ESC Guidelines for the Management of Cardiovascular Diseases during Pregnancy. European Heart Journal, 39, 3165-3241. https://doi.org/10.1093/eurheartj/ehy340
|
[29]
|
Martinelli, I., et al. (2016) Recurrent Venous Thromboembolism and Abnormal Uterine Bleeding with Anticoagulant and Hormone Therapy Use. Blood, 127, 1417-1425. https://doi.org/10.1182/blood-2015-08-665927
|
[30]
|
Scheres, L., et al. (2018) Abnormal Vaginal Bleeding in Women of Reproductive Age Treated with Edoxaban or Warfarin for Venous Thromboembolism: A Post Hoc Analysis of the Hokusai-VTE Study. BJOG, 125, 1581-1589.
https://doi.org/10.1111/1471-0528.15388
|
[31]
|
Brekelmans, M.P., et al. (2017) Abnormal Vaginal Bleeding in Women with Venous Thromboembolism Treated with Apixaban or Warfarin. Thrombosis and Haemostasis, 117, 809-815. https://doi.org/10.1160/TH16-11-0874
|
[32]
|
Huisman, M.V., et al. (2018) Less Abnormal Uterine Bleed-ing with Dabigatran than Warfarin in Women Treated for Acute Venous Thromboembolism. J Thrombosis and Haemo-stasis, 16, 1775-1778. https://doi.org/10.1111/jth.14226
|
[33]
|
van Es, N., et al. (2014) Direct Oral Anticoagulants Compared with Vitamin K Antagonists for Acute Venous Thromboembolism: Evidence from Phase 3 Trials. Blood, 124, 1968-1975. https://doi.org/10.1182/blood-2014-04-571232
|
[34]
|
Tritschler, T., et al. (2018) Venous Thromboem-bolism: Advances in Diagnosis and Treatment. JAMA, 320, 1583-1594.
https://doi.org/10.1001/jama.2018.14346
|
[35]
|
Tektonidou, M.G., et al. (2019) EULAR Recommendations for the Management of Antiphospholipid Syndrome in Adults. Annals of Rheumatic Diseases, 78, 1296-1304. https://doi.org/10.1136/annrheumdis-2019-215213
|
[36]
|
Zuily, S., et al. (2020) Use of Direct Oral Anticoagulants in Patients with Thrombotic Antiphospholipid Syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Journal of Thrombosis and Haemostasis, 18, 2126-2137. https://doi.org/10.1111/jth.14935
|
[37]
|
Maggio, A., et al. (2022) Pulmonary Embolism in Children, a Real Chal-lenge for the Pediatrician: A Case Report and Review of the Literature. Acta Biomedica, 93, e2022055.
|
[38]
|
Henderson, L.A., et al. (2020) On the Alert for Cytokine Storm: Immunopathology in COVID-19. Arthritis & Rheumatology, 72, 1059-1063. https://doi.org/10.1002/art.41285
|
[39]
|
工作组新型冠状病毒感染住院患者血栓预防和抗凝管理临床路径与实施规范等, 新型冠状病毒感染住院患者血栓预防和抗凝管理临床路径与实施规范[J]. 中华结核和呼吸杂志, 2023: 1-16.
|